
Lung cancer has a low survival rate and is increasing in incidence worldwide. Immune checkpoint inhibitors (ICIs) have recently changed the treatment landscape for individuals with advanced solid tumors, with numerous clinical studies having demonstrated that the addition of ICIs—such as antibodies specific for programmed cell death–1 (PD-1) or for its ligand PD-L1—to platinum-based combination chemotherapy results in a significant extension...
Like
Save
Share